Zhitong Finance App News, Li Jing Pacific (00575) issued an announcement. The board of directors is pleased to provide the latest progress on preparations for the launch of Accrua Health™ (renamed Accrua Health™ from Accrua™, “Accrua Health”, or Deep Longevity's consumer digital health and telemedicine platform in the US). It is currently anticipated that the launch will take place in the fourth quarter of 2026. A trial launch for invitees only will be launched in the fourth quarter of 2026, followed by a public waiting list phase, and finally a full commercial launch. This brief delay reflects the time it took to introduce Deep Longevity's telemedicine infrastructure partner and digital advertising agency, and to ensure that Deep Longevity's BloodAge reports were seamlessly integrated into one of the partners' electronic health record (EHR) platforms. The Board believes this investment will lay a solid operating foundation for a successful launch.
Accrua Health will be launched in stages, so Deep Longevity can launch marketing and accumulate the number of patients as soon as possible, while establishing a solid operating foundation before expanding its range of services. The first phase will cover medical weight loss, longevity, and anti-aging peptide drugs; the second phase will add testosterone and hormone replacement therapy; and the third phase will launch more projects based on patient demographics, needs, and evolving business priorities. As part of its strategy to deepen the layout of the US healthcare ecosystem, Deep Longevity is also working to ensure compliance with the requirements of the Health Insurance Portability and Accountability Act (HIPAA) to coincide with the launch.